PTC Therapeutics (PTCT) Tops Q3 EPS by $1.32

PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of $0.20, $1.32 better than the analyst estimate of ($1.12). Revenue for the quarter came in at $211 million versus the consensus estimate of $174.39 million.

GUIDANCE:

PTC Therapeutics sees FY2025 revenue of $750-800 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results